🎉 M&A multiples are live!
Check it out!

Regencell Bioscience Valuation Multiples

Discover revenue and EBITDA valuation multiples for Regencell Bioscience and similar public comparables like Pharming, Julphar, and Vivoryon Therapeutics.

Regencell Bioscience Overview

About Regencell Bioscience

Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people’s immune systems.


Founded

2014

HQ

United States of America
Employees

12

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$417M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Regencell Bioscience Financials

Regencell Bioscience has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Regencell Bioscience achieved revenue of n/a and an EBITDA of -$4.0M.

Regencell Bioscience expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Regencell Bioscience valuation multiples based on analyst estimates

Regencell Bioscience P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$5.5M -$4.0M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$7.4M -$5.9M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Regencell Bioscience Stock Performance

As of April 15, 2025, Regencell Bioscience's stock price is $33.

Regencell Bioscience has current market cap of $425M, and EV of $417M.

See Regencell Bioscience trading valuation data

Regencell Bioscience Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$417M $425M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Regencell Bioscience Valuation Multiples

As of April 15, 2025, Regencell Bioscience has market cap of $425M and EV of $417M.

Regencell Bioscience's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Regencell Bioscience's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Regencell Bioscience and 10K+ public comps

Regencell Bioscience Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $417M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -104.4x XXX XXX XXX
P/E -98.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -104.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Regencell Bioscience Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Regencell Bioscience Valuation Multiples

Regencell Bioscience's NTM/LTM revenue growth is n/a

Regencell Bioscience's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.4M for the same period.

Over next 12 months, Regencell Bioscience's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Regencell Bioscience's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Regencell Bioscience and other 10K+ public comps

Regencell Bioscience Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -27% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.4M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Regencell Bioscience Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Regencell Bioscience M&A and Investment Activity

Regencell Bioscience acquired  XXX companies to date.

Last acquisition by Regencell Bioscience was  XXXXXXXX, XXXXX XXXXX XXXXXX . Regencell Bioscience acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Regencell Bioscience

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Regencell Bioscience

When was Regencell Bioscience founded? Regencell Bioscience was founded in 2014.
Where is Regencell Bioscience headquartered? Regencell Bioscience is headquartered in United States of America.
How many employees does Regencell Bioscience have? As of today, Regencell Bioscience has 12 employees.
Who is the CEO of Regencell Bioscience? Regencell Bioscience's CEO is Mr. Yat-Gai Au.
Is Regencell Bioscience publicy listed? Yes, Regencell Bioscience is a public company listed on NAS.
What is the stock symbol of Regencell Bioscience? Regencell Bioscience trades under RGC ticker.
When did Regencell Bioscience go public? Regencell Bioscience went public in 2021.
Who are competitors of Regencell Bioscience? Similar companies to Regencell Bioscience include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Regencell Bioscience? Regencell Bioscience's current market cap is $425M
Is Regencell Bioscience profitable? Yes, Regencell Bioscience is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.